KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19.

Pedro Landete, Olga-Adriana Caliman-Sturdza, Jose A Lopez-Martin, Liliana Preotescu, Mihaela-Catalina Luca, Anastasia Kotanidou, Paula Villares, Shirley-Patricia Iglesias, Pablo Guisado-Vasco, Elena-Maria Saiz-Lou, Maria Del Carmen Farinas-Alvarez, Esperanza Merino de Lucas, Eduardo Perez-Alba, Jose-Miguel Cisneros, Vicente Estrada, Carmen Hidalgo-Tenorio, Garyfallia Poulakou, Miguel Torralba, Jesus Fortun, Paula Garcia-Ocana, Adrien Lemaignen, Miguel Marcos-Martin, Maria Molina, Roger Paredes, Maria Teresa Perez-Rodriguez, Dimitar Raev, Pablo Ryan, Fernanda Meira, Javier Gomez, Nadia Torres, Diego Lopez-Mendoza, Jose Jimeno, Jose-Felipe Varona

Clin Infect Dis 79(4) 910-919

PMID39182994
PMCIDPMC11478586
DOI10.1093/cid/ciae227
发表日期2024-08-25
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Plitidepsin has shown potent preclinical activity against severe acute respiratory syndrome coronavirus 2 and was generally well tolerated in a phase I trial of hospitalized patients with coronavirus disease 2019 (COVID-19). NEPTUNO, a phase III, multicenter, randomized, controlled trial, was designed to evaluate the efficacy and safety of plitidepsin in the management of moderate COVID-19 in hospitalized adult patients. METHODS: Included patients had documented severe acute respiratory syndrome coronavirus 2 infection, required oxygen therapy, and had adequate organ function. The planned sample size was 609 patients. Patients were randomized 1:1:1 to at least 3 days of dexamethasone plus either plitidepsin (1.5 mg/day or 2.5 mg/day, for 3 days) or standard of care (control). The primary endpoint was the time to sustained withdrawal of supplemental oxygen. Secondary endpoints included time to sustained hospital discharge, clinical status, duration of oxygen support, percentage of patients requiring admission to the intensive care unit, and safety. RESULTS: After randomizing 205 patients, NEPTUNO was discontinued due to a notable drop in COVID-19-related hospitalizations. Available data suggest a 2-day improvement in the median time to sustained oxygen therapy discontinuation (5 vs 7 days) favoring both plitidepsin arms (hazard ratio, 1.37; 95% confidence interval, .96-1.96; P = .08 for plitidepsin 1.5 mg vs control; hazard ratio, 1.06; 95% confidence interval, .73-1.53; P = .78 for plitidepsin 2.5 mg vs control). Plitidepsin was generally well tolerated. CONCLUSIONS: Despite the trial limitations, these results suggest that plitidepsin may have a positive benefit-risk ratio in the management of patients requiring oxygen therapy. Further studies with plitidepsin, including those in immunosuppressed patients, are warranted.Results from this phase III trial suggest that plitidepsin, a first-in-class antiviral, may have a positive benefit-risk ratio in the management of hospitalized patients requiring oxygen therapy for moderate COVID-19.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。